tradingkey.logo
tradingkey.logo
Search

Cocrystal Pharma Inc

COCP
Add to Watchlist
1.050USD
+0.020+1.94%
Close 06/30, 16:00ETQuotes delayed by 15 min
14.48MMarket Cap
LossP/E TTM

TradingKey Stock Score of Cocrystal Pharma Inc

Currency: USD Updated: 2026-06-30

Key Insights

Cocrystal Pharma Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 144 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cocrystal Pharma Inc's Score

Industry at a Glance

Industry Ranking
144 / 387
Overall Ranking
268 / 4569
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Cocrystal Pharma Inc Highlights

StrengthsRisks
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Undervalued
The company’s latest PE is -1.45, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 769.42K shares, decreasing 3.50% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.83.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
9.000
Target Price
+773.79%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Cocrystal Pharma Inc?

The TradingKey Stock Score provides a comprehensive assessment of Cocrystal Pharma Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Cocrystal Pharma Inc’s performance and outlook.

How do we generate the financial health score of Cocrystal Pharma Inc?

To generate the financial health score of Cocrystal Pharma Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Cocrystal Pharma Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Cocrystal Pharma Inc.

How do we generate the company valuation score of Cocrystal Pharma Inc?

To generate the company valuation score of Cocrystal Pharma Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Cocrystal Pharma Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Cocrystal Pharma Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Cocrystal Pharma Inc.

How do we generate the earnings forecast score of Cocrystal Pharma Inc?

To calculate the earnings forecast score of Cocrystal Pharma Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Cocrystal Pharma Inc’s future.

How do we generate the price momentum score of Cocrystal Pharma Inc?

When generating the price momentum score for Cocrystal Pharma Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Cocrystal Pharma Inc’s prices. A higher score indicates a more stable short-term price trend for Cocrystal Pharma Inc.

How do we generate the institutional confidence score of Cocrystal Pharma Inc?

To generate the institutional confidence score of Cocrystal Pharma Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Cocrystal Pharma Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Cocrystal Pharma Inc.

How do we generate the risk management score of Cocrystal Pharma Inc?

To assess the risk management score of Cocrystal Pharma Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Cocrystal Pharma Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Cocrystal Pharma Inc.